Key result
Promoter-driven action potential imaging enables rapid subtype-specific phenotyping of hiPSC cardiomyocytes.
Development of a method for rapid, sequential, and subtype-specific phenotyping of hiPSC-CMs to improve disease modeling and drug testing.
Cardiomyocytes (CMs) generated from human induced pluripotent stem cells (hiPSCs) are increasingly used in disease modelling and drug evaluation. However, they are typically a heterogeneous mix of ventricular-, atrial-, and nodal-like cells based on action potentials (APs) and gene expression. This heterogeneity and the paucity of methods for highthroughput functional phenotyping hinder the full exploitation of their potential. We aimed at developing a method for rapid, sequential, and subtype-specific phenotyping of hiPSC-CMs with respect to AP morphology and single-cell arrhythmias.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2016) studied Disease modelling and drug testing in hiPSC-derived cardiomyocytes. Subtype-specific promoter-driven action potential imaging was evaluated on Development of a method for rapid, sequential, and subtype-specific phenotyping of hiPSC-CMs. Subtype-specific promoter-driven action potential imaging was proposed to enable rapid, sequential, and subtype-specific phenotyping of hiPSC-derived cardiomyocytes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: